Today: 16 May 2026
Browse Category

NYSE:RNG 23 February 2026 - 24 February 2026

RingCentral stock steadies before the bell after 12% slide as Piper Sandler lifts target

RingCentral stock steadies before the bell after 12% slide as Piper Sandler lifts target

RingCentral shares rose 0.6% to $34.79 in premarket trading Tuesday after a 12.5% drop Monday and a 34% jump Friday. Piper Sandler raised its price target to $37 but kept a neutral rating, citing pricing pressure and dilution risk. The board approved a quarterly dividend of $0.075 per share, payable March 16 to holders as of March 9. Investors are watching if the post-earnings rally holds.
24 February 2026
··
RingCentral stock slips in premarket as Piper Sandler lifts target after dividend-driven surge

RingCentral stock slips in premarket as Piper Sandler lifts target after dividend-driven surge

RingCentral shares fell 0.8% to $39.20 premarket Monday after surging 34.6% Friday on news of a new dividend and strong cash-flow outlook. Piper Sandler raised its price target to $37 but kept a Neutral rating. The company reported 2025 revenue of $2.515 billion and free cash flow up 32% to $530 million. Investors are watching if cash returns and customer retention hold through 2026.
23 February 2026
··
RingCentral stock price near $40 in premarket after 34% jump — what Wall Street is watching now

RingCentral stock price near $40 in premarket after 34% jump — what Wall Street is watching now

RingCentral shares traded near $39.50 premarket Monday after jumping 34.4% Friday, following a new dividend, expanded buyback, and strong free cash flow forecast. Oppenheimer, Rosenblatt, Mizuho, and Morgan Stanley all raised price targets, citing AI momentum and margin gains. The company is integrating OpenAI’s GPT-5.2 for enterprise voice AI. Revenue growth for 2026 is projected at 4% to 5%.
23 February 2026
·

Stock Market Today

  • Valneva Q1 2026 Earnings: Revenue Decline, Vaccine Progress, and Cost Cuts
    May 16, 2026, 5:15 AM EDT. Valneva SE reported first-quarter 2026 revenues of about €30 million, marking a decline due to business setup changes, supply phasing, and one-off expenses. The company announced a 10-15% workforce reduction aiming for a 25-35% cut in operating costs. Valneva is advancing its Lyme disease vaccine with Pfizer, which plans regulatory filing despite statistical challenges. The Chikungunya vaccine is progressing with pilot campaigns in Brazil. Due to weak travel vaccine uptake, 2026 sales guidance was revised down to €135-150 million. The Shigella vaccine program continues development with ongoing studies. Management remains confident in long-term vaccine prospects and strategic growth.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 16.05.2026

16 May 2026
LIVEMarkets rolling coverageStarted: May 16, 2026, 4:00 AM EDTUpdated: May 16, 2026, 5:16 AM EDT Morgan Stanley Revises Nebius Stock Price Target After Strong AI Cloud Quarter May 16, 2026, 5:16 AM EDT. Morgan Stanley raised its price target for Nebius following a significant quarter in the AI cloud segment, reflecting the company’s robust performance in this growing area. Despite the upward revision, the bank remains cautious and is not aggressively pursuing the stock amid the broader rally. This tempered stance suggests Morgan Stanley acknowledges Nebius’s potential while weighing market risks and valuation concerns. Morgan Stanley resets Nebius stock price
Dow Drops 537 Points With After-Hours Selling Threatening Wall Street AI Rally

Dow Drops 537 Points With After-Hours Selling Threatening Wall Street AI Rally

16 May 2026
U.S. stock ETFs fell in after-hours trading Friday following a more than 1% drop in the S&P 500, Dow, and Nasdaq. Oil surged 4.2% to $105.42 a barrel and the 10-year Treasury yield hit 4.597%, fueling concerns over inflation and Fed rate hikes. Nvidia, AMD, and Intel led chip declines, while Berkshire Hathaway disclosed a $2.65 billion Delta stake and exited Amazon, Visa, and Mastercard.
Accuray inks 10-year cancer tech agreement, shares in focus

Accuray inks 10-year cancer tech agreement, shares in focus

16 May 2026
Accuray and the University of Wisconsin School of Medicine and Public Health signed a 10-year research agreement focused on Accuray’s Stellar adaptive radiotherapy platform. The announcement came after market close, with Accuray shares ending down 5.2% at $0.27. The deal follows Accuray’s recent withdrawal of fiscal 2026 guidance and ongoing financial pressures.
Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

16 May 2026
Origin Materials asked shareholders to approve a plan to liquidate and dissolve the company, estimating an initial payout of $0.61 to $3.54 per share depending on asset sales and claims. Shares rose 15% to $1.43 after the filing. The company reported a 91% drop in first-quarter revenue and warned it may not survive without the wind-down. Origin cut 59% of its workforce and CEO John Bissell stepped down May 1.
Go toTop